Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 7/20 | 0.46 |
| ▸ | JAK1 | P23458 | 7/20 | 0.46 |
| ▸ | TYK2 | P29597 | 7/20 | 0.46 |
| ▸ | JAK3 | P52333 | 7/20 | 0.46 |
| ▸ | KDR | P35968 | 6/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.46 |
| ▸ | ABL1 | P00519 | 2/20 | 0.44 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 5/20 | 0.41 |
| ▸ | ATAD2 | Q6PL18 | 5/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23332369 | 1.00 | JAK2 (0.46) | JAK2JAK1TYK2JAK3KDR | |
| SCHEMBL23332429 | 0.94 | PRKCZ (0.50) | JAK2JAK1TYK2JAK3KDR | |
| SCHEMBL25044168 | 0.89 | JAK2 (0.44) | JAK2JAK1TYK2JAK3KDR | |
| SCHEMBL25044286 | 0.88 | ABL1 (0.45) | JAK2JAK1TYK2JAK3KDR | |
| SCHEMBL30175753 | 0.88 | ABL1 (0.45) | JAK2JAK1TYK2JAK3KDR | |
| SCHEMBL30175700 | 0.87 | KDR (0.60) | JAK2JAK1TYK2JAK3KDR | |
| SCHEMBL25043284 | 0.87 | KDR (0.60) | JAK2JAK1TYK2JAK3KDR | |
| SCHEMBL29897444 | 0.86 | CYP1A2 (0.47) | JAK2JAK1TYK2JAK3ABL1 | |
| SCHEMBL23301100 | 0.86 | CYP1A2 (0.47) | JAK2JAK1TYK2JAK3ABL1 | |
| SCHEMBL23301135 | 0.85 | KDR (0.53) | JAK2JAK1TYK2JAK3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637428-B2 | Isoquinoline derivatives as SIK2 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| US-20230045929-A1 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637428-B2 | Isoquinoline derivatives as SIK2 inhibitors | SIK2, SIK1, SIK3 | JAK2 54/4885JAK1 123/4885TYK2 16/4885 |
| US-20230045929-A1 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | SIK2, SIK3, SIK1 | JAK2 13/4885JAK1 58/4885TYK2 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.